Earlier this week, a committee of experts had deferred a decision on the request of SII to start trials and asked the company to amend its protocol for the clinical study. The subject expert committee (SEC) had recommended eight amendments to be made to the firm's proposal to conduct Phase-II and -III trials.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3jYXQyT
via IFTTT
0 comments:
Post a Comment